Current Report Filing (8-k)
October 20 2020 - 7:52AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event
reported): October 20, 2020
BRAIN SCIENTIFIC INC.
(Exact Name of Registrant as Specified
in Charter)
Nevada
|
|
333-209325
|
|
81-0876714
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
125 Wilbur Place, Suite 170
Bohemia, NY 11716
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number,
including area code: (917) 388-1578
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Not applicable
|
|
Not applicable
|
|
Not applicable
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging Growth Company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☒
Item
7.01 Regulation FD Disclosure.
On October 20, 2020, Brain Scientific Inc.
(the “Company”) issued a press release announcing the appointment of Stuart Bernstein as Vice President of Marketing.
In this role, Mr. Bernstein will be responsible for the Company’s overall marketing strategy and efforts to strengthen the
Company’s market position.
The information in this Item 7.01 and in
Exhibit 99.1 of Item 9.01 is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This
report will not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1 of Item 9.01.
Item
9.01 Financial Statements and Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: October 20, 2020
|
BRAIN SCIENTIFIC INC.
|
|
|
|
By:
|
/s/ Boris Goldstein
|
|
Name:
|
Boris Goldstein
|
|
Title:
|
Chairman of the Board, Secretary and
Executive Vice President
|
2
Brain Scientific (CE) (USOTC:BRSF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Brain Scientific (CE) (USOTC:BRSF)
Historical Stock Chart
From Jul 2023 to Jul 2024